Pregnancy Outcome Following First-Trimester Exposure to Bilastine: A Comparative Observational Cohort Study from the Israeli Teratology Information Service

Reem Hegla-Murad, Svetlana Shechtman, Orna Diav-Citrin · 2026

Read Pregnancy Outcome Following First-Trimester Exposure to Bilastine: A Comparative Observational Cohort Study from the Israeli Teratology Information Service by Reem Hegla-Murad, Svetlana Shechtman, Orna Diav-Citrin (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13362734.txt.

Description

Reem Hegla-Murad, Svetlana Shechtman, and Orna Diav-Citrin report a 2026 pregnancy safety study on bilastine, a non-drowsy allergy drug. Human data on its use in pregnancy were thin. The team followed women who called an Israeli advice service after taking the drug in the first trimester between 2019 and 2023. They then compared outcomes with women who took another allergy drug, fexofenadine.

Follow-up covered 36 bilastine pregnancies. Major birth defects appeared at a rate close to the comparison group, with no shared pattern of defects. Live birth rates were high, and loss rates were low. The authors call the results early reassurance for women exposed by chance, while stressing that the group is small and larger studies must confirm the picture.

Catalog record

CREATORReem Hegla-Murad, Svetlana Shechtman, Orna Diav-Citrin
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE19317
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13362734

Browse the full library · About the Tower of Babel